New horizons in hepatitis C antiviral therapy with direct-acting antivirals. (Q38087250)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467911%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

title

New horizons in hepatitis C antiviral therapy with direct-acting antivirals (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467911%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467911%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Raffaele De Francesco

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467911%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author name string

Alessio Aghemo

series ordinal

1

1 reference

28 August 2017

Raffaele De Francesco

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

31 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467911%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467911%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

volume

58

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467911%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467911%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

page(s)

428-438

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467911%20AND%20SRC:MED&resulttype=core&format=json

New insights into structure and replication of the hepatitis C virus and clinical implications

25 February 2020

cites work

1 reference

Boceprevir: a protease inhibitor for the treatment of hepatitis C.

21 January 2018

1 reference

Telaprevir for the treatment of hepatitis C.

21 January 2018

1 reference

The role of resistance in HCV treatment

21 January 2018

1 reference

Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease

21 January 2018

1 reference

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).

21 January 2018

1 reference

Rapid and sharp decline in HCV upon monotherapy with NS3 protease inhibitor, ACH-1625.

21 January 2018

1 reference

Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease

21 January 2018

1 reference

In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor

21 January 2018

1 reference

Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

21 January 2018

1 reference

Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity

21 January 2018

1 reference

MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

21 January 2018

1 reference

Antiviral strategies in hepatitis C virus infection

21 January 2018

1 reference

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants

21 January 2018

1 reference

The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors

21 January 2018

1 reference

Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase

21 January 2018

1 reference

Identification of Hepatitis C Virus NS5A Inhibitors

21 January 2018

1 reference

Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture

21 January 2018

1 reference

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

21 January 2018

1 reference

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.

21 January 2018

1 reference

Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein

21 January 2018

1 reference

Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay

21 January 2018

1 reference

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

21 January 2018

1 reference

Resistance to direct antiviral agents in patients with hepatitis C virus infection

21 January 2018

1 reference

Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus

21 January 2018

1 reference

Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site

21 January 2018

1 reference

Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

21 January 2018

1 reference

Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase

21 January 2018

1 reference

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin

21 January 2018

1 reference

Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus

21 January 2018

1 reference

Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate

21 January 2018

1 reference

Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796

21 January 2018

1 reference

HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus

21 January 2018

1 reference

The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function

21 January 2018

1 reference

New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B.

21 January 2018

1 reference

Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis

21 January 2018

1 reference

Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.

21 January 2018

1 reference

Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus

21 January 2018

1 reference

The antimalarial ferroquine is an inhibitor of hepatitis C virus.

21 January 2018

1 reference

Second-wave protease inhibitors: choosing an heir

21 January 2018

1 reference

Second generation direct antivirals and the way to interferon-free regimens in chronic HCV.

21 January 2018

1 reference

Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents

21 January 2018

1 reference

Hepatitis C therapy in non-genotype 1 patients: the near future

21 January 2018

1 reference

The NS5A replication complex inhibitors: difference makers?

21 January 2018

1 reference

Preliminary study of two antiviral agents for hepatitis C genotype 1.

21 January 2018

1 reference

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

21 January 2018

1 reference

Mixing and matching drugs: what makes sense?

21 January 2018

1 reference

Treatment predictors of a sustained virologic response in hepatitis B and C.

21 January 2018

1 reference

TMC435 for the treatment of chronic hepatitis C.

21 January 2018

1 reference

Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation

21 January 2018

1 reference

Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis

21 January 2018

1 reference

New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.

21 January 2018

1 reference

Is hepatitis virus resistance to antiviral drugs a threat?

21 January 2018

1 reference

Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052.

21 January 2018

1 reference

Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV-1 null responders

21 January 2018

1 reference

Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HEP.26371

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23467911%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference